FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1019-1026 September 11, 2003 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Hart, R. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation–related stroke is not known but is central to the choice of the target INR.

Methods We studied incident ischemic strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation. Strokes were identified through hospitalization data bases and validated on the basis of medical records, which also provided information on the use of warfarin or aspirin, the INR at admission, and coexisting illnesses. The severity of stroke was graded according to a modified Rankin scale. Thirty-day mortality was ascertained from hospitalization and mortality files.

Results Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy. Among patients who were taking warfarin, an INR of less than 2.0 at admission, as compared with an INR of 2.0 or greater, independently increased the odds of a severe stroke in a proportional-odds logistic-regression model (odds ratio, 1.9; 95 percent confidence interval, 1.1 to 3.4) across three severity categories and the risk of death within 30 days (hazard ratio, 3.4; 95 percent confidence interval, 1.1 to 10.1). An INR of 1.5 to 1.9 at admission was associated with a mortality rate similar to that for an INR of less than 1.5 (18 percent and 15 percent, respectively). The 30-day mortality rate among patients who were taking aspirin at the time of the stroke was similar to that among patients who were taking warfarin and who had an INR of less than 2.0.

Conclusions Among patients with nonvalvular atrial fibrillation, anticoagulation that results in an INR of 2.0 or greater reduces not only the frequency of ischemic stroke but also its severity and the risk of death from stroke. Our findings provide further evidence against the use of lower INR target levels in patients with atrial fibrillation.

Source Information

From the General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston (E.M.H., Y.C., L.E.H., D.E.S.); the Division of Research, Kaiser Permanente of Northern California, Oakland (A.S.G., N.G.J., J.V.S.); and the Departments of Epidemiology, Biostatistics, and Medicine, University of California, San Francisco, San Francisco (A.S.G.).

Address reprint requests to Dr. Hylek at the General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, 50 Staniford St., 9th Fl., Boston, MA 02114.

Full Text of this Article

Related Letters:

Oral Anticoagulation and Stroke in Atrial Fibrillation
Folkeringa R. J., Dinh T. N.H., Crijns H. J.G.M., Epstein E. F., Natarajan I., Boos C. J., Hylek E. M., Go A. S., Singer D. E.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2360-2361, Dec 11, 2003. Correspondence

This article has been cited by other articles:

• Crandall, M. A., Bradley, D. J., Packer, D. L., Asirvatham, S. J. (2009). Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. Mayo Clin Proc. 84: 643-662 [Abstract] [Full Text]  
• Cios, D. A., Baker, W. L., Sander, S. D., Phung, O. J., Coleman, C. I. (2009). Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis. Am J Health Syst Pharm 66: 916-925 [Abstract] [Full Text]  
• Gladstone, D. J., Bui, E., Fang, J., Laupacis, A., Lindsay, M. P., Tu, J. V., Silver, F. L., Kapral, M. K. (2009). Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated. Stroke 40: 235-240 [Abstract] [Full Text]  
• Quinn, T. J., Ray, G., Atula, S., Walters, M. R., Dawson, J., Lees, K. R. (2008). Deriving Modified Rankin Scores From Medical Case-Records. Stroke 39: 3421-3423 [Abstract] [Full Text]  
• Oake, N. MSc, Jennings, A. MA, Forster, A. J. MD MSc, Fergusson, D. PhD, Doucette, S. MSc, van Walraven, C. MD MSc (2008). Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 179: 235-244 [Abstract] [Full Text]  
• Garcia, D. A, Witt, D. M, Hylek, E., Wittkowsky, A. K, Nutescu, E. A, Jacobson, A., Moll, S., Merli, G. J, Crowther, M., Earl, L., Becker, R. C, Oertel, L., Jaffer, A., Ansell, J. E (2008). Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum. The Annals of Pharmacotherapy 42: 979-988 [Abstract] [Full Text]  
• Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G. (2008). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S [Abstract] [Full Text]  
• Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., Ansell, J. (2008). The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 299S-339S [Abstract] [Full Text]  
• Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J. (2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S [Abstract] [Full Text]  
• Toyoda, K., Yasaka, M., Iwade, K., Nagata, K., Koretsune, Y., Sakamoto, T., Uchiyama, S., Gotoh, J., Nagao, T., Yamamoto, M., Takahashi, J. C., Minematsu, K., for the Bleeding with Antithrombotic Therapy (BAT), (2008). Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study. Stroke 39: 1740-1745 [Abstract] [Full Text]  
• Lane, D. A., Lip, G. Y.H. (2008). Barriers to Anticoagulation in Patients With Atrial Fibrillation: Changing Physician-Related Factors. Stroke 39: 7-9 [Full Text]  
• Nutescu, E. A. (2007). ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. Am J Health Syst Pharm 64: 2281-2291 [Full Text]  
• Liao, J., Khalid, Z., Scallan, C., Morillo, C., O'Donnell, M. (2007). Noninvasive Cardiac Monitoring for Detecting Paroxysmal Atrial Fibrillation or Flutter After Acute Ischemic Stroke: A Systematic Review. Stroke 38: 2935-2940 [Abstract] [Full Text]  
• Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. ANN INTERN MED 146: 857-867 [Abstract] [Full Text]  
• Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., Regan, S. (2007). Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation. Circulation 115: 2689-2696 [Abstract] [Full Text]  
• Oake, N., Fergusson, D. A., Forster, A. J., van Walraven, C. (2007). Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 176: 1589-1594 [Abstract] [Full Text]  
• Lane, D. A., Lip, G. Y. H. (2007). Maintaining Therapeutic Anticoagulation: The Importance of Keeping "Within Range". Chest 131: 1277-1279 [Full Text]  
• van Walraven, C., Oake, N., Wells, P. S., Forster, A. J. (2007). Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromobembolic Events in the Elderly. Chest 131: 1508-1515 [Abstract] [Full Text]  
• Doty, J. R., Doty, D. B., Jones, K. W., Flores, J. H., Mensah, M., Reid, B. B., Clayson, S. E., Snow, G., Righter, E., Millar, R. C. (2007). Comparison of standard Maze III and radiofrequency Maze operations for treatment of atrial fibrillation. J. Thorac. Cardiovasc. Surg. 133: 1037-1044 [Abstract] [Full Text]  
• White, H. D., Gruber, M., Feyzi, J., Kaatz, S., Tse, H.-F., Husted, S., Albers, G. W. (2007). Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control: Results From SPORTIF III and V. Arch Intern Med 167: 239-245 [Abstract] [Full Text]  
• Gillinov, A. M. (2007). Advances in Surgical Treatment of Atrial Fibrillation. Stroke 38: 618-623 [Abstract] [Full Text]  
• Aguilar, M. I., Hart, R. G., Kase, C. S., Freeman, W. D., Hoeben, B. J., Garcia, R. C., Ansell, J. E., Mayer, S. A., Norrving, B., Rosand, J., Steiner, T., Wijdicks, E. F. M., Yamaguchi, T., Yasaka, M. (2007). Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion. Mayo Clin Proc. 82: 82-92 [Abstract] [Full Text]  
• Dunning, J., Treasure, T., Versteegh, M., Nashef, S. A.M., on behalf of the EACTS Audit and Guidelines Commit, (2006). Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur. J. Cardiothorac. Surg. 30: 852-872 [Full Text]  
• Hylek, E. M., Henault, L. E., Evans-Molina, C., Shea, C., Regan, S. (2006). Response to Letter by Testa et al. Stroke 37: 2868-2868 [Full Text]  
• Writing Committee Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 651-745 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: 854-906 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: e149-e246 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752 [Full Text]  
• Authors/Task Force Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 27: 1979-2030 [Full Text]  
• Lakshminarayan, K., Solid, C. A., Collins, A. J., Anderson, D. C., Herzog, C. A. (2006). Atrial Fibrillation and Stroke in the General Medicare Population: A 10-Year Perspective (1992 to 2002). Stroke 37: 1969-1974 [Abstract] [Full Text]  
• Dentali, F., Douketis, J. D, Woods, K., Thabane, L., Foster, G., Holbrook, A., Crowther, M. (2006). Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial. The Annals of Pharmacotherapy 40: 1241-1247 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e873-e923 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 1583-1633 [Abstract] [Full Text]  
• Hylek, E. M., D'Antonio, J., Evans-Molina, C., Shea, C., Henault, L. E., Regan, S. (2006). Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation. Stroke 37: 1075-1080 [Abstract] [Full Text]  
• Garcia, D. A., Regan, S., Crowther, M., Hylek, E. M. (2006). The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy. J Am Coll Cardiol 47: 804-808 [Abstract] [Full Text]  
• Currie, C J, Jones, M, Goodfellow, J, McEwan, P, Morgan, C L, Emmas, C, Peters, J R (2006). Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 92: 196-200 [Abstract] [Full Text]  
• Bushi, D., Grad, Y., Einav, S., Yodfat, O., Nishri, B., Tanne, D. (2005). Hemodynamic Evaluation of Embolic Trajectory in an Arterial Bifurcation: An In-Vitro Experimental Model. Stroke 36: 2696-2700 [Abstract] [Full Text]  
• Sundt, T. M., Gersh, B. J. (2005). Making Sense of the Maze: Which Patients With Atrial Fibrillation Will Benefit?. JAMA 294: 2357-2359 [Full Text]  
• Waldo, A. L., Becker, R. C., Tapson, V. F., Colgan, K. J., for the NABOR Steering Committee, (2005). Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. J Am Coll Cardiol 46: 1729-1736 [Abstract] [Full Text]  
• Camerlingo, M., Salvi, P., Belloni, G., Gamba, T., Cesana, B. M., Mamoli, A. (2005). Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infarctions. Stroke 36: 2415-2420 [Abstract] [Full Text]  
• McBride, B. F. (2005). A Preliminary Assessment of the Critical Differences Between Novel Oral Anticoagulants Currently in Development. J Clin Pharmacol 45: 1004-1017 [Abstract] [Full Text]  
• Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., Cook, J. R. (2005). Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit. ANN INTERN MED 143: 241-250 [Abstract] [Full Text]  
• Kirchhof, P., Monnig, G., Wasmer, K., Heinecke, A., Breithardt, G., Eckardt, L., Bocker, D. (2005). A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 26: 1292-1297 [Abstract] [Full Text]  
• Hart, R. G., Tonarelli, S. B., Pearce, L. A. (2005). Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas. Stroke 36: 1588-1593 [Abstract] [Full Text]  
• Garcia, D., Regan, S., Crowther, M., Hughes, R. A., Hylek, E. M. (2005). Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population. Chest 127: 2049-2056 [Abstract] [Full Text]  
• Katira, R, Chauhan, A, More, R S (2005). Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad. Med. J. 81: 370-375 [Abstract] [Full Text]  
• Bath, P. M.W., Zhao, L., Heptinstall, S. (2005). Current status of stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C12-C18 [Abstract] [Full Text]  
• O'Donnell, M., Agnelli, G., Weitz, J. I. (2005). Emerging therapies for stroke prevention in atrial fibrillation. Eur Heart J Suppl 7: C19-C27 [Abstract] [Full Text]  
• Emmerich, J., Le Heuzey, J.-Y., Bath, P. M.W., Connolly, S. J. (2005). Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. Eur Heart J Suppl 7: C28-C33 [Abstract] [Full Text]  
• Schulman, S., Beyth, R. J. (2005). Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl 7: C34-C40 [Abstract] [Full Text]  
• Miller, P. S.J., Drummond, M. F., Langkilde, L. K., McMurray, J. J.V., Ogren, M. (2005). Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C41-C54 [Abstract] [Full Text]  
• O'Brien, C. L., Gage, B. F. (2005). Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. JAMA 293: 699-706 [Abstract] [Full Text]  
• Miller, P. S.J., Andersson, F. L., Kalra, L. (2005). Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated?. Stroke 36: 360-366 [Abstract] [Full Text]  
• Kim, H. J., Arora, R. (2005). Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril. J CARDIOVASC PHARMACOL THER 10: 11-21 [Abstract]  
• Scholten, M. F., Thornton, A. S., Mekel, J. M., Koudstaal, P. J., Jordaens, L. J. (2005). Anticoagulation in atrial fibrillation and flutter. Europace 7: 492-499 [Abstract] [Full Text]  
• Page, R. L. (2004). Newly Diagnosed Atrial Fibrillation. NEJM 351: 2408-2416 [Full Text]  
• Reynolds, M. W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C., Nalysnyk, L. (2004). Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis. Chest 126: 1938-1945 [Abstract] [Full Text]  
• Fang, M. C., Chang, Y., Hylek, E. M., Rosand, J., Greenberg, S. M., Go, A. S., Singer, D. E. (2004). Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. ANN INTERN MED 141: 745-752 [Abstract] [Full Text]  
• Dager, W. E, Vondracek, T. G, McIntosh, B. A, Nutescu, E. A (2004). Ximelagatran: An Oral Direct Thrombin Inhibitor. The Annals of Pharmacotherapy 38: 1881-1897 [Abstract] [Full Text]  
• Kucher, N., Connolly, S., Beckman, J. A., Cheng, L. H., Tsilimingras, K. V., Fanikos, J., Goldhaber, S. Z. (2004). International Normalized Ratio Increase Before Warfarin-Associated Hemorrhage: Brief and Subtle. Arch Intern Med 164: 2176-2179 [Abstract] [Full Text]  
• Steger, C., Pratter, A., Martinek-Bregel, M., Avanzini, M., Valentin, A., Slany, J., Stollberger, C. (2004). Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 25: 1734-1740 [Abstract] [Full Text]  
• Dunning, J., Nagarajan, D. V., Amanullah, M., Nouraei, S. M. (2004). What is the optimal anticoagulation management of patients post-cardiac surgery who go into atrial fibrillation?. ICVTS 3: 503-509 [Abstract] [Full Text]  
• Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., Manning, W. J. (2004). Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 429S-456S [Abstract] [Full Text]  
• Dager, W. E. (2004). Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation. J CARDIOVASC PHARMACOL THER 9: 151-162 [Abstract]  
• O'Rourke, F., Dean, N., Akhtar, N., Shuaib, A. (2004). Current and future concepts in stroke prevention. CMAJ 170: 1123-1133 [Abstract] [Full Text]  
• Folkeringa, R. J., Dinh, T. N.H., Crijns, H. J.G.M., Epstein, E. F., Natarajan, I., Boos, C. J., Hylek, E. M., Go, A. S., Singer, D. E. (2003). Oral Anticoagulation and Stroke in Atrial Fibrillation. NEJM 349: 2360-2361 [Full Text]  
• Malik, I. (2003). JournalScan. Heart 89: 1467-1468 [Full Text]  
• Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., Singer, D. E. (2003). Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?. JAMA 290: 2685-2692 [Abstract] [Full Text]  
• (2003). Stroke Severity and Intensity of Anticoagulation in Atrial Fibrillation. JWatch Gastroenterology 2003: 8-8 [Full Text]  
• (2003). Anticoagulation Intensity Matters in Patients with Nonvalvular Afib. Journal Watch Cardiology 2003: 1-1 [Full Text]  
• (2003). More Evidence for Moderate-Intensity Warfarin. JWatch Neurology 2003: 1-1 [Full Text]  
• Singer, D. E. (2003). A 60-Year-Old Woman With Atrial Fibrillation. JAMA 290: 2182-2189 [Full Text]  
• (2003). Stroke Severity and Intensity of Anticoagulation in Atrial Fibrillation. JWatch General 2003: 2-2 [Full Text]  
• Tanne, J. H. (2003). Study shows what INR level is best for preventing stroke in patients with atrial fibrillation. BMJ 327: 638-638 [Full Text]